JNCCN study reveals neuroendocrine tumor mortality patterns to inform treatment decisions

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A study published in JNCCN—Journal of the National  Comprehensive Cancer Network demonstrated that among all patients with neuroendocrine tumors, the risk of dying of  cancer was higher than that of dying of other causes—but mortality varies by primary tumor site. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

“Backwater to Blockbuster,” the first de novo book published by the Cancer History Project, traces the evolution of St. Jude Children’s Research Hospital to its current status of a powerhouse of research in pediatric cancer.

The U.S. Department of Justice issued a letter alleging that Yale Medical School of violating anti-discrimination laws and instititing policies that disadvantaged white and Asian applicants while favoring Black and Hispanic applicants.  The DOJ investigation, which was launched a year ago, reviewed the school’s admission policies for the class of 2023, 2024, and 2025, the...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login